Latest Almac Stories

She’ll oversee Myoderm’s revolutionary turnkey sourcing service. Norristown, PA (PRWEB) January 08, 2013 Myoderm, a global leader in sourcing commercial drugs for clinical trials, is pleased to announce that Tracie DiPasquale has joined the company as Director, CentralSource. She will work out of Myoderm’s US office. Myoderm is fortunate to have someone with Tracie’s background and qualifications to direct CentralSource, the company’s turnkey sourcing, distribution, and...

PARSIPPANY, N.J., Oct. 8, 2012 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed a collaboration agreement with the Almac Group Ltd. (UK) in the field of biocatalysis to provide sustainable manufacturing services to the pharmaceutical industry. The agreement grants both parties access to their enzyme platform technologies, services and expertise for the...

UPPSALA, Sweden, December 6, 2011 /PRNewswire/ -- Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Almac Discovery Ltd., an independent member of the Almac Group Ltd. Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint(TM), to identify high-quality fragment hits against a number of undisclosed targets of therapeutic interest to Almac Discovery. "We are proud...

CRAIGAVON, Northern Ireland, May 11, 2011 /PRNewswire/ -- Almac is hosting its inaugural European Product Launch workshop in Boston, MA on 17th May 2011. Targeted specifically at the biopharmaceutical sector, the workshop provides consultative advice and services to US companies to successfully launch drug products onto the European market. The workshop will provide US companies with important market and regulatory framework knowledge, whilst guiding them through the European...

CRAIGAVON, Northern Ireland, May 6, 2011 /PRNewswire/ -- Almac's Clinical Technologies business unit announced today that Todd Kole has joined the Company as Vice President of Clinical Project Services (CPS) and a member of the Executive Leadership Team. As Vice President of CPS, Todd will report directly to the President of Almac Clinical Technologies and will oversee clinical project management and drug supply services globally. Mr. Kole has extensive experience in the...

CRAIGAVON, Northern Ireland, May 4, 2011 /PRNewswire/ -- - Almac's Biocatalysis Business Continues its Strong Growth and Boosts its Visibility With the Launch of the selectAZymeTM Brand As anticipated, Almac's biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical companies and continued growth of...

CRAIGAVON, NI, April 11, 2011 /PRNewswire/ -- - Award Recognises Almac's Continued Growth Success and Presence as a World Class Player in Pharmaceutical and Biotech Services The Almac Group, headquartered in Craigavon Northern Ireland, is celebrating another highly impressive year after being named 'Business of the Year' (for the second time in 3 years), together with other significant accolades at the Northern Ireland business awards - run by the nation's main daily...

Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd have developed a new treatment for cancer which rather than attacking tumors directly, prevents the growth of new blood vessels in tumors, starving them of oxygen and nutrients, thereby preventing their growth.Targeting tumor blood vessels is not a new concept, however, this drug attacks the blood vessels using an entirely different pathway and therefore could be useful for treating tumors which don't...

CRAIGAVON, Northern Ireland, April 4, 2011 /PRNewswire/ -- - Scientists at Almac and Queen's University Belfast Discover Novel Approach to Treat Cancer Patients New Study findings published in Clinical Cancer Research - The Journal of the American Association of Cancer Research (AACR) Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd, announce the first publication describing a potential new anti-angiogenic therapy based on a...

CRAIGAVON, Northern Ireland, March 30, 2011 /PRNewswire/ -- Almac's Diagnostics business unit today announced the opening of its CLIA registered laboratory. The opening of the Almac CLIA Laboratory supports the company's ongoing Biomarker Discovery and Development Strategy by enabling the use of novel tests to stratify and enrich prospective clinical trails. This ability is of key importance as Almac begins to transition the novel biomarkers that they have developed into clinical...